Press Releases

Press Releases

View all news
Voronoi Passes Technology Evaluation
2021.06.22
⚫ Secures A grade from Korea Technology Finance Corporation... Expected to pursue listing within the year

Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies, announced on the 22nd that it has received an A grade from the Korea Technology Finance Corporation (KIBO), a technology evaluation institution designated by the Korea Exchange.

Voronoi explained that the result reflects recognition of its differentiated technological capabilities, including: the construction of a kinase profiling database on par with global big pharma; securing the largest volume of annual experimental data in Korea through the internalization of core capabilities such as its laboratory animal center; and improved efficiency through continuous feedback between its wet lab and artificial intelligence (AI). Voronoi had already demonstrated its technological strength last year by licensing out an EGFR exon20 insertion mutation therapeutic compound to ORIC Pharmaceuticals, a NASDAQ-listed U.S. company, for total milestones of USD 621 million. With this, Voronoi was recorded as the only unlisted company among the seven Korean pharmaceutical and biotech companies that completed large-scale overseas license-out deals last year. In addition, following a joint research agreement with JW Pharmaceutical on the STAT3 target in the PROTAC field at the end of last year, Voronoi licensed out a RET fusion-targeting anticancer drug to the Korean pharmaceutical company HK inno.N early this year.
CEO Daekwon Kim of Voronoi said, "Since last year's global license-out, the capabilities of our R&D and business development divisions have been expanding along a J-curve. We will continue to deliver license-out results with precision targeted kinase anticancer drugs that show outstanding selectivity and blood-brain-barrier penetration." Voronoi, which failed the technology evaluation in 2019, is now able to re-challenge for a KOSDAQ listing after two years. This is because the Korea Exchange reformed its technology evaluation system, effective April 26, to streamline the technology evaluation procedure for companies with excellent market valuations, allowing companies with a market capitalization of KRW 500 billion or more to be reviewed based on an evaluation by a single institution (with a result of A or higher).